Fibromyalgia Treatment Market Segmented By Anti-depressants, Anticonvulsants, Muscle Relaxants, Analgesics by Drugs
Industry: Healthcare
Published Date: December-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 231
Report ID: PMRREP32455
The global revenue from the fibromyalgia treatment market stands at US$ 1.3 Bn in 2022, with the global market expected to grow at a CAGR of 7.0% to reach a valuation of approximately US$ 2.7 Bn by the end of 2033.
|
Market Size (2022) |
US$ 1.3 Bn |
|
Projected Market Value (2033) |
US$ 2.7 Bn |
|
Global Market Growth Rate (2023-2033) |
7.0% CAGR |
|
Market Share of Top 5 Countries |
64.4% |
North America is expected to hold the largest market share during the forecast period, due to the high prevalence of fibromyalgia in the region and the availability of advanced treatment options. However, the Asia Pacific region is expected to grow at the fastest CAGR during the forecast period, due to the increasing awareness of fibromyalgia and the rising demand for effective treatment options in the region.
The fibromyalgia treatment market is segmented by type of treatment into pharmaceutical treatments and non-pharmaceutical treatments. Pharmaceutical treatments are further segmented into antidepressants, anticonvulsants, muscle relaxants, and Analgesics. Non-pharmaceutical treatments are further segmented into physical therapy, cognitive-behavioral therapy (CBT), and other therapies, such as acupuncture and massage therapy.
The global market recorded a historic CAGR of 5.0% in the last 6 years from 2016 to 2022.
In addition to affecting the patient's quality of life, fibromyalgia (FM) is a somatization disorder that is characterised by widespread, chronic musculoskeletal pain. Since the only sign of the illness is invisible pain, the symptoms also have an impact on the patient's emotional state.
The epidemiology of fibromyalgia was demonstrated by COPCORD Community Oriented Program for the Control of Rheumatic Diseases, the London Fibromyalgia Epidemiology Study Screening Questionnaire, and ACR American College of Rheumatology. Fibromyalgia is recognised to be characterised by persistent, widespread pain, restless sleep, physical weariness, and cognitive challenges. With a prevalence of between 2% and 4% in general populations, it affects all populations worldwide.
Depression, chronic fatigue syndrome, panic attacks, irritable bowel syndrome, anxiety, and post-traumatic stress disorder are just a few of the "functional" problems that commonly coexist with FM. As a condition of central sensitization, fibromyalgia is frequently categorised as a pain regulation disorder.
Despite the lack of evidence of a particular candidate gene, several investigations have indicated a genetic propensity for fibromyalgia.
Sensitization, which includes central sensitivity syndromes such as joint stiffness and chronic pain at several tender spots as well as systemic symptoms including cognitive impairment, sleep problems, anxiety, exhaustion, and depressive episodes, is the main cause of FM. FM is a diverse condition that is frequently linked to particular illnesses including infections, mental or neurological conditions, diabetes, and rheumatic pathologies.
Females are more likely to experience FM, which causes musculoskeletal discomfort, considerably lowers quality of life, frequently necessitates unexpected medical attention, and has ongoing social consequences.
By taking into account the risk-benefit ratio of any medication, a patient-tailored approach typically necessitates pharmacological treatment. FM prevalence appears to range from 1.3-8% in the general population, making it the third most prevalent diagnosis in rheumatology clinics, as per the American College of Rheumatology (2016).
The market is anticipated to expand as a result of factors which include growing research and development expenditures for the discovery of new therapies for the treatment of fibromyalgia and the approval and launch of novel fibromyalgia treatment drugs.
The global market is thus likely to show high growth over the coming years at a CAGR of 7.0% and reach a global market size of US$ 2.7 Bn by 2033.
“Investigation of Novel Drugs and Potential Applications of Combination Therapy”
Fibromyalgia is a chronic condition whose symptoms severely impair patients' capacity to participate in typical social and occupational activities and make it challenging to uphold regular connections with family, friends, and co-workers.
None of the treatments that are now on the market is completely effective against the full range of pain, exhaustion, sleep disruptions, and depressive symptoms.
However, the growing initiatives by the pharmaceutical sector have resulted in the introduction of new experimental drugs, new combinations of existing drugs, as well as investigations of the opportunity to utilize drugs presently being prescribed for other diseases.
Additionally, combination therapy is a new concept that warrants additional investigation while new experimental drugs and modified versions of existing drugs have occasionally demonstrated promising results in recent years. The introduction of more efficient ways to improve the quality of life of patients with FM has been made possible by a greater understanding of the role played by the central nervous system and the peripheral nervous system in processing pain as well as the emergence of associated symptoms.
This continues to be a challenge and evidently demands for multidisciplinary treatment, which will propel further research and development activities by the pharmaceutical companies, thus driving the global market for fibromyalgia treatment.
“Lack of Approved Medications, Limitations to Therapeutic Efficacy, Lack of Reimbursements, and Poor Treatment Compliance”
The US FDA has only given its approval to a small number of medications for the treatment of FM, whilst the European Medicines Agency has not given its approval to any drugs for this indication. As a result, FM patients frequently require off-label treatment.
Drugs currently only effectively reduce pain by 25% to 40%, and substantial alleviation only occurs in 40% to 60% of patients, in part because of dose-limiting side effects and inadequate treatment response. For the treatment of FM, the available pharmacotherapies are frequently unsuccessful and poorly tolerated.
Because multiple studies have reported a lack of efficacy in controlling symptoms, they have been unable to prove which treatment is the best. As a result, the various management guidelines range in their recommendations and therefore are dependent on expert opinion, which varies from case to case.
Fibromyalgia is a chronic, idiopathic syndrome that is more common in women and is characterised by widespread, all-over pain. The pathophysiology of it is still unknown. Its chronic nature suggests a solely symptomatic, frequently ineffective, course of treatment. It is rather typical for people to not follow the prescribed course of treatment.
Prescription trends are significantly influenced by insurance coverage. Given the market's predominance of off-label and generic medications in the current environment, it is challenging for insurers to offer coverage for recently introduced branded medications.
When compared to off-label products, the cost of treatment using already approved medications like Cymbalta, Lyrica, and Savella is higher. A coinsurance or co-pay will be part of the out-of-pocket expenses for patients whose insurance covers them.
As a result, another factor limiting the use of the fibromyalgia drug is the high treatment cost, which is also limiting the market's overall growth for fibromyalgia treatment.
These factors thus limit the expansion of the market over the forecast period.
Why is the U.S. Market Booming?
“Emergence of Generics”
The U.S. is set to account for around 39.8% market share in the global market in 2023.
Due to its prospective consumer base, recent product introductions, and the presence of top manufacturers there, the market is anticipated to have the largest market share in the global fibromyalgia treatment market during the course of the projected period. Additionally, generic drug producers like Teva Pharmaceutical Industries Ltd., Mylan N.V., and others have introduced generic medications in the North American region, supporting market expansion.
Pharmaceutical companies including Prismic Pharmaceuticals, Inc., Aptinyx, Inc., and Innovative Med Concepts, Inc. all have fibromyalgia treatments in pipeline.
Will Germany Be a Lucrative Market for Fibromyalgia Treatment?
“Increasing Healthcare Expenditure”
Germany is set to hold around 5.0% market share of the global market in 2023.
In Europe, there has not yet been a fibromyalgia therapy option that has received regulatory approval. Pregabalin, amitriptyline, and duloxetine are suggested for short-term use in the German S3 guideline. Germany's market is predicted to develop as a result of the lack of fibromyalgia treatment choices and new product introductions.
Additionally, the European Commission's increasing healthcare spending is anticipated to boost the local economy.
How is China Emerging as a Prominent Country in the Fibromyalgia Treatment Market?
“Rising Prevalence of Rheumatic Diseases and Associated Co-Morbidities”
China held a market share of about 46.4% of the East Asia market in 2022.
The main factors influencing the Chinese fibromyalgia market include the country's ageing population, rising rates of rheumatic diseases, increased public awareness, and rising incidents of traumatic stress disorder and traffic accidents. The functional status of people with rheumatoid arthritis is worsened by fibromyalgia and associated symptoms, per a 2017 study that was published in the journal Arthritis Care & Research. Co-morbid fibromyalgia syndrome affects 15% to 30% of individuals with rheumatic diseases.
The high prevalence of disease thus propels the market for fibromyalgia treatment in the country.
Which Drug is Driving Demand within the Global Market?
“Effective Management of Pain Related Indications”
The anticonvulsants segment dominated the global market in 2022 and are expected to hold a 35% of market share.
Adjuvant analgesics are a component of anticonvulsants, sometimes known as seizure drugs. Accordingly, although not being intended for that purpose, they can manage some forms of chronic pain. Anticonvulsants, such pregabalin, have shown a small advantage over a placebo in terms of lowering pain and sleep difficulties.
These medications also have a greater treatment adherence, thus propelling the anticonvulsants segment to drive the global market for fibromyalgia treatment.
Which Distribution Channel Offers the Market a Profitable Outlook?
“Availability and Accessibility of Treatment Modalities”
Hospital pharmacies will hold a larger share of about 45.9% in 2023.
Drugs and generics for the treatment and management of fibromyalgia are largely accessible through hospital pharmacies. With a large burden of disease, patients prefer institutional settings such as hospitals for the diagnosis, as well as the treatment of disease indications that affect their daily quality of life.
Ease of accessibility to therapeutic options, availability of subsidized costs of medication or treatment regimen, as well as a greater adoption of pharmacological therapies for fibromyalgia treatment, are factors propelling the growth of the hospital pharmacies segment within the global market.
The presence of both established and emerging market players sets the global market for fibromyalgia treatments apart. These players are actively making significant investments in R&D to develop novel therapies. Due to this, there is a substantial pipeline of prospective products that are progressing in clinical investigations.
As a result, it is projected that the introduction of treatment modalities with the capability for commercial viability will stimulate market expansion and assist manufacturers consolidate their positions in the global market.
Some key instances of development include:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the fibromyalgia treatment market, which are available in the full report.
|
Attribute |
Details |
|
Forecast Period |
2023-2033 |
|
Historical Data Available for |
2016-2022 |
|
Market Analysis |
USD Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Covered |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Drug Class:
Distribution Channel:
Region:
To know more about delivery timeline for this report Contact Sales
The global market is currently valued at around US$ 1.3 Bn in 2022.
Sales of the market are set to witness growth at a CAGR of 7.0% and be valued at around US$ 2.7 Bn by 2033.
Demand for the global market increased at a 5.0% CAGR from 2016 to 2022.
U.S., Japan, China, Canada, and Germany account for most demand within the market, currently holding around 64.4% market share.
The U.S. is set to account for around 39.8% market share in the global market in 2023
Latin America accounts for around 8.3% share of the global market in 2022.
Germany is set to hold around 5.0% market share of the global market in 2023.
China held a market share of about 46.4% of the East Asia market in 2022.
The fibromyalgia treatment market in India is set to expand at a 10.8% CAGR over the forecast period.
